Literature DB >> 8058164

Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis.

P Rieckmann1, M Albrecht, B Kitze, T Weber, H Tumani, A Broocks, W Lüer, S Poser.   

Abstract

We determined the cytokine messenger RNA (mRNA) expression pattern of blood mononuclear cells in 45 patients with the relapsing-remitting form of MS and 32 patients with other neurologic diseases. Using a semiquantitative polymerase chain reaction method, we detected significantly higher levels of tumor necrosis factor-alpha and lymphotoxin mRNA in patients with relapsing compared to those with stable disease (p < 0.001), but transforming growth factor-beta and interleukin-10 mRNA expressions were higher in patients with stable disease.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8058164     DOI： 10.1212/wnl.44.8.1523

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  28 in total

1.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Authors:  Jennifer L Gommerman; Keith Giza; Stuart Perper; Irene Sizing; Apinya Ngam-Ek; Cheryl Nickerson-Nutter; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

4.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

5.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

Authors:  K Genç; D L Dona; A T Reder
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 6.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

7.  Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.

Authors:  A Créange; L Bélec; B Clair; J D Degos; J C Raphaël; R K Gherardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

8.  TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10.

Authors:  David J Huss; Ryan C Winger; Haiyan Peng; Yuhong Yang; Michael K Racke; Amy E Lovett-Racke
Journal:  J Immunol       Date:  2010-04-14       Impact factor: 5.422

9.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 10.  Multiple sclerosis therapy. A practical guide.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.